Announced details
Artificial hip joint systems
The Group sells products through a joint venture it established in China. Details of the equity ownership ratio and personnel relationships are Not disclosed.
A joint venture established in Changzhou, Jiangsu Province, China. Other company details are Not disclosed.
China's National Medical Products Administration
Medical device approval number: 国械注准 20263131244. The validity period is Not disclosed.
Changzhou, Jiangsu Province, China (WOMA)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Entrada Stem Collarless（Hydroxylapatite coating collarless femoral stem）, Entrada Stem Collared（Hydroxylapatite coating collared femoral stem）, Femoral head（Ceramic Head）, Escalade Cup（Acetabular Cup）, Escalade Liner（Acetabular Liner） |
| Counterparty | Changzhou Waston Ortho Medical Appliance Co., Limited (WOMA) |
| Counterparty overview | A joint venture established in Changzhou, Jiangsu Province, China. Other company details are Not disclosed. |
| Relationship with the Company | The Group sells products through a joint venture it established in China. Details of the equity ownership ratio and personnel relationships are Not disclosed. |
| Launch date | December 2026 (sales scheduled to begin) |
| Applicable area | Artificial hip joint systems |
| Awarding / certifying body | China's National Medical Products Administration |
| Registration number and expiry date | Medical device approval number: 国械注准 20263131244. The validity period is Not disclosed. |
| Location | Changzhou, Jiangsu Province, China (WOMA) |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To add Entrada Hip Stem-related products to the lineup of products already approved, provide healthcare professionals with a broader range of product choices, expand sales in the Chinese market, and strengthen the business foundation.